

<b>Statement of Deficiencies</b>	<b>(X1) Provider/Supplier/CLIA Identification Number</b> 28D0679425	<b>(X3) Date Survey Completed</b> 11/28/2022
<b>Name of Provider or Supplier</b> Beatrice Community Hospital & Health Center	<b>Street Address, City, State</b> 4800 Hospital Parkway, Beatrice, NE	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

<b>(X4) ID Prefix Tag</b>	<b>Summary Statement of Deficiencies</b>
<b>D2016</b>	<p><b>SUCCESSFUL PARTICIPATION</b> CFR(s): 493.803(a)(b)(c)</p> <p>(a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history.</p> <p>This CONDITION is not met as evidenced by: Based on an off-site desk review of the laboratory's 2022 American Proficiency Institute proficiency testing (PT) records and a telephone interview with the laboratory manager on November 28, 2022, it was determined the laboratory failed to successfully participate in proficiency testing for the analyte D(Rho). Refer to D2162.</p>
<b>D2162</b>	<p><b>ABO GROUP AND D(RHO) TYPING</b> CFR(s): 493.859(f)</p> <p>Failure to achieve satisfactory performance for the same analyte in two consecutive</p>

testing events or two out of three consecutive testing events is unsuccessful performance.

This STANDARD is not met as evidenced by:

Based on proficiency testing (PT) desk review, the laboratory's graded PT results from American Proficiency Institute (API), and a phone interview with the laboratory manager, the laboratory failed to achieve satisfactory performance for the D(Rho) analyte in two consecutive testing events. Findings are: 1. The laboratory obtained an unsatisfactory score of 80% for the D(Rho) analyte in the first testing event of 2022. 2. The laboratory obtained an unsatisfactory score of 80% for the D(Rho) analyte in the second testing event of 2022. 3. Phone interview with the laboratory manager on November 28, 2022 at 11:43 AM confirmed the laboratory failed to achieve a satisfactory performance for the D(Rho) analyte in the first and second PT events for 2022.